Enamine and Ewha Partner to Close the Loop Between AI Design and Real-World Chemistry

KYIV, UKRAINE, October 7, 2026 /EINPresswire.com/ -- Enamine Ltd., a global leader in chemistry for drug discovery, and the Global AI Drug Discovery Center at Ewha Womans University today signed a Memorandum of Understanding (MOU) establishing a long-term strategic partnership in AI-driven drug discovery. Signed at a ceremony on the Ewha campus in Seoul, the agreement unites the Center’s expertise in artificial intelligence (AI), computational chemistry and data-driven drug design with Enamine’s synthetically accessible chemical space, rapid synthesis and biological testing. Together, the partners aim to shorten the path from computational hypothesis to experimentally validated hit and lead compounds.

Artificial intelligence can now propose promising molecules faster than ever, but a design creates value only when it can be made and tested. The partnership addresses this gap by building a closed design–make–test–analyze (DMTA) cycle: AI models search within and learn from Enamine’s synthetically accessible chemical space, while prioritized compounds are synthesized and experimentally tested, and the resulting data feed back into the next round of designs.

𝐅𝐫𝐨𝐦 𝐚𝐥𝐠𝐨𝐫𝐢𝐭𝐡𝐦 𝐭𝐨 𝐯𝐚𝐥𝐢𝐝𝐚𝐭𝐞𝐝 𝐜𝐨𝐦𝐩𝐨𝐮𝐧𝐝
𝐃𝐞𝐬𝐢𝐠𝐧 𝐰𝐢𝐭𝐡𝐢𝐧 𝐚𝐜𝐜𝐞𝐬𝐬𝐢𝐛𝐥𝐞 𝐜𝐡𝐞𝐦𝐢𝐜𝐚𝐥 𝐬𝐩𝐚𝐜𝐞. Enamine will give the Center access to its catalogues of in-stock building blocks and screening compounds and to its ultra-large REAL (REadily AccessibLe) chemical spaces of make-on-demand molecules for AI-based virtual screening, generative design and model training.

𝐌𝐚𝐤𝐞 𝐯𝐢𝐫𝐭𝐮𝐚𝐥 𝐜𝐨𝐦𝐩𝐨𝐮𝐧𝐝𝐬 𝐫𝐞𝐚𝐥, 𝐟𝐚𝐬𝐭. Molecules designed or selected by the Center can be synthesized rapidly from available reagents, using reactions with experimentally validated reactivity to achieve high success rates and short delivery times.

𝐓𝐞𝐬𝐭 𝐚𝐧𝐝 𝐥𝐞𝐚𝐫𝐧. Enamine’s biology team will profile selected compounds on-site using biochemical, biophysical, and cell-based assays, as well as early ADME studies, providing rapid feedback to refine the AI models.

Sun Choi, Director, Global AI Drug Discovery Center at Ewha Womans University: “𝘈 𝘮𝘢𝘫𝘰𝘳 𝘤𝘩𝘢𝘭𝘭𝘦𝘯𝘨𝘦 𝘪𝘯 𝘈𝘐-𝘥𝘳𝘪𝘷𝘦𝘯 𝘥𝘳𝘶𝘨 𝘥𝘪𝘴𝘤𝘰𝘷𝘦𝘳𝘺 𝘪𝘴 𝘵𝘳𝘢𝘯𝘴𝘭𝘢𝘵𝘪𝘯𝘨 𝘤𝘰𝘮𝘱𝘶𝘵𝘢𝘵𝘪𝘰𝘯𝘢𝘭𝘭𝘺 𝘱𝘳𝘰𝘮𝘪𝘴𝘪𝘯𝘨 𝘮𝘰𝘭𝘦𝘤𝘶𝘭𝘦𝘴 𝘪𝘯𝘵𝘰 𝘤𝘰𝘮𝘱𝘰𝘶𝘯𝘥𝘴 𝘵𝘩𝘢𝘵 𝘤𝘢𝘯 𝘢𝘤𝘵𝘶𝘢𝘭𝘭𝘺 𝘣𝘦 𝘴𝘺𝘯𝘵𝘩𝘦𝘴𝘪𝘻𝘦𝘥 𝘢𝘯𝘥 𝘦𝘹𝘱𝘦𝘳𝘪𝘮𝘦𝘯𝘵𝘢𝘭𝘭𝘺 𝘷𝘢𝘭𝘪𝘥𝘢𝘵𝘦𝘥. 𝘞𝘦 𝘩𝘢𝘷𝘦 𝘢𝘱𝘱𝘭𝘪𝘦𝘥 𝘰𝘶𝘳 𝘈𝘐 𝘢𝘯𝘥 𝘤𝘰𝘮𝘱𝘶𝘵𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘥𝘳𝘶𝘨 𝘥𝘦𝘴𝘪𝘨𝘯 𝘤𝘢𝘱𝘢𝘣𝘪𝘭𝘪𝘵𝘪𝘦𝘴 𝘵𝘰𝘨𝘦𝘵𝘩𝘦𝘳 𝘸𝘪𝘵𝘩 𝘮𝘦𝘥𝘪𝘤𝘪𝘯𝘢𝘭 𝘤𝘩𝘦𝘮𝘪𝘴𝘵𝘳𝘺 𝘢𝘯𝘥 𝘣𝘪𝘰𝘭𝘰𝘨𝘪𝘤𝘢𝘭 𝘷𝘢𝘭𝘪𝘥𝘢𝘵𝘪𝘰𝘯 𝘢𝘤𝘳𝘰𝘴𝘴 𝘢 𝘳𝘢𝘯𝘨𝘦 𝘰𝘧 𝘵𝘩𝘦𝘳𝘢𝘱𝘦𝘶𝘵𝘪𝘤 𝘢𝘳𝘦𝘢𝘴. 𝘉𝘺 𝘤𝘰𝘮𝘣𝘪𝘯𝘪𝘯𝘨 𝘵𝘩𝘪𝘴 𝘦𝘹𝘱𝘦𝘳𝘪𝘦𝘯𝘤𝘦 𝘸𝘪𝘵𝘩 𝘌𝘯𝘢𝘮𝘪𝘯𝘦’𝘴 𝘢𝘤𝘤𝘦𝘴𝘴𝘪𝘣𝘭𝘦 𝘤𝘩𝘦𝘮𝘪𝘤𝘢𝘭 𝘴𝘱𝘢𝘤𝘦, 𝘳𝘢𝘱𝘪𝘥 𝘴𝘺𝘯𝘵𝘩𝘦𝘴𝘪𝘴 𝘢𝘯𝘥 𝘣𝘪𝘰𝘭𝘰𝘨𝘪𝘤𝘢𝘭 𝘵𝘦𝘴𝘵𝘪𝘯𝘨, 𝘸𝘦 𝘢𝘪𝘮 𝘵𝘰 𝘤𝘳𝘦𝘢𝘵𝘦 𝘢 𝘱𝘰𝘸𝘦𝘳𝘧𝘶𝘭 𝘱𝘭𝘢𝘵𝘧𝘰𝘳𝘮 𝘧𝘰𝘳 𝘱𝘳𝘰𝘴𝘱𝘦𝘤𝘵𝘪𝘷𝘦 𝘢𝘯𝘥 𝘪𝘵𝘦𝘳𝘢𝘵𝘪𝘷𝘦 𝘥𝘳𝘶𝘨 𝘥𝘪𝘴𝘤𝘰𝘷𝘦𝘳𝘺.”

Iaroslava Kos, Director, Business Development at Enamine: “𝘌𝘯𝘢𝘮𝘪𝘯𝘦’𝘴 𝘤𝘩𝘦𝘮𝘪𝘤𝘢𝘭 𝘴𝘱𝘢𝘤𝘦 𝘸𝘢𝘴 𝘣𝘶𝘪𝘭𝘵 𝘵𝘰 𝘣𝘦 𝘮𝘢𝘥𝘦, 𝘯𝘰𝘵 𝘫𝘶𝘴𝘵 𝘪𝘮𝘢𝘨𝘪𝘯𝘦𝘥. 𝘗𝘢𝘳𝘵𝘯𝘦𝘳𝘪𝘯𝘨 𝘸𝘪𝘵𝘩 𝘌𝘸𝘩𝘢’𝘴 𝘎𝘭𝘰𝘣𝘢𝘭 𝘈𝘐 𝘋𝘳𝘶𝘨 𝘋𝘪𝘴𝘤𝘰𝘷𝘦𝘳𝘺 𝘊𝘦𝘯𝘵𝘦𝘳 𝘱𝘶𝘵𝘴 𝘵𝘩𝘢𝘵 𝘴𝘱𝘢𝘤𝘦 𝘪𝘯 𝘵𝘩𝘦 𝘩𝘢𝘯𝘥𝘴 𝘰𝘧 𝘰𝘶𝘵𝘴𝘵𝘢𝘯𝘥𝘪𝘯𝘨 𝘈𝘐 𝘴𝘤𝘪𝘦𝘯𝘵𝘪𝘴𝘵𝘴, 𝘢𝘯𝘥 𝘸𝘦 𝘢𝘳𝘦 𝘱𝘳𝘰𝘶𝘥 𝘵𝘰 𝘣𝘶𝘪𝘭𝘥 𝘢 𝘭𝘢𝘴𝘵𝘪𝘯𝘨 𝘴𝘤𝘪𝘦𝘯𝘵𝘪𝘧𝘪𝘤 𝘣𝘳𝘪𝘥𝘨𝘦 𝘣𝘦𝘵𝘸𝘦𝘦𝘯 𝘜𝘬𝘳𝘢𝘪𝘯𝘦 𝘢𝘯𝘥 𝘒𝘰𝘳𝘦𝘢.”

𝐀 𝐛𝐫𝐨𝐚𝐝 𝐩𝐥𝐚𝐭𝐟𝐨𝐫𝐦 𝐟𝐨𝐫 𝐥𝐨𝐧𝐠-𝐭𝐞𝐫𝐦 𝐜𝐨𝐨𝐩𝐞𝐫𝐚𝐭𝐢𝐨𝐧
Beyond the core design–make–test cycle, the partners will conduct joint research in synthesizability-aware generative design, ultra-large virtual screening, reaction and property prediction, and the generation of high-quality experimental data for model training, and will publish results together. They will also explore integrated drug discovery offerings that take projects from AI-based design to validated hits and leads for pharmaceutical, biotechnology and academic partners in Korea and worldwide.

The agreement further provides for joint applications to Korean government R&D programs, Horizon Europe and bilateral Korea–Ukraine initiatives; exchanges of faculty, researchers and students; internships and training in AI-driven drug design and in synthetic and medicinal chemistry; and joint symposiums, workshops and seminars. Together, these activities will strengthen the drug discovery ecosystems of both countries and open new opportunities with academic, industrial and governmental partners across Asia, Europe and beyond.

𝐀𝐛𝐨𝐮𝐭 𝐄𝐧𝐚𝐦𝐢𝐧𝐞 𝐋𝐭𝐝.
Enamine is a leading provider of chemical compounds for drug discovery and a scientifically driven contract research organization offering integrated drug discovery services, with unique partnering opportunities in exploring new chemical space. The company combines access to in-house-produced screening compounds (4.8 million in stock) and building blocks (375,000 in stock) with a comprehensive platform of discovery services in bioinformatics, biology and chemistry to advance and accelerate drug discovery.
Learn more: www.enamine.net

𝐀𝐛𝐨𝐮𝐭 𝐄𝐧𝐚𝐦𝐢𝐧𝐞 𝐑𝐄𝐀𝐋
Enamine REAL (REadily AccessibLe) is a chemical space of billions of synthetically feasible molecules that Enamine can synthesize rapidly (typically in 3–4 weeks), with a high success rate (over 80%) and at low cost. REAL compounds are designed by combining 203,000 in-stock building blocks through 169 well-validated parallel synthesis protocols, an approach built to maximize synthesis success.
Learn more: https://enamine.net/compound-collections/real-compounds

𝐀𝐛𝐨𝐮𝐭 𝐭𝐡𝐞 𝐆𝐥𝐨𝐛𝐚𝐥 𝐀𝐈 𝐃𝐫𝐮𝐠 𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲 𝐂𝐞𝐧𝐭𝐞𝐫 𝐚𝐭 𝐄𝐰𝐡𝐚 𝐖𝐨𝐦𝐚𝐧𝐬 𝐔𝐧𝐢𝐯𝐞𝐫𝐬𝐢𝐭𝐲
The Global AI Drug Discovery Center at Ewha Womans University integrates artificial intelligence (AI) and computer-aided drug design (CADD) with physics- and mechanism-based computational chemistry, molecular simulation, medicinal chemistry, and biological validation to advance innovative drug discovery. The Center promotes interdisciplinary and international collaboration across AI/CADD, computational and medicinal chemistry, and biology, with a particular emphasis on translating computational hypotheses into experimentally validated compounds and actionable drug discovery outcomes. The Center has conducted collaborative drug discovery research across a broad range of therapeutic areas with universities, research institutes, and industry partners in Korea and internationally.
Learn more: http://caddsc.ewha.ac.kr/

𝐌𝐞𝐝𝐢𝐚 𝐜𝐨𝐧𝐭𝐚𝐜𝐭𝐬

Oleksii Gavrylenko
Enamine Ltd
Visit us on social media:
LinkedIn
Instagram
Facebook
X